These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 27485438)

  • 1. Benefit assessment in Germany: implications for price discounts.
    Theidel U; von der Schulenburg JM
    Health Econ Rev; 2016 Dec; 6(1):33. PubMed ID: 27485438
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Benefit Assessment and Price Negotiation Under AMNOG: Calculable Process or Unfair Poker Game?].
    Radic D; Haugk S; Radic M
    Gesundheitswesen; 2018 Jun; 80(6):573-579. PubMed ID: 27636366
    [TBL] [Abstract][Full Text] [Related]  

  • 3. From Indication-Based Pricing to Blended Approach: Evidence on the Price and Reimbursement Negotiation in Italy.
    Rossini EE; Galeone C; Lucchetti C; Jommi C
    Pharmacoecon Open; 2024 Mar; 8(2):251-261. PubMed ID: 38228997
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lessons From The Impact Of Price Regulation On The Pricing Of Anticancer Drugs In Germany.
    Lauenroth VD; Kesselheim AS; Sarpatwari A; Stern AD
    Health Aff (Millwood); 2020 Jul; 39(7):1185-1193. PubMed ID: 32634355
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural changes in the German pharmaceutical market: price setting mechanisms based on the early benefit evaluation.
    Henschke C; Sundmacher L; Busse R
    Health Policy; 2013 Mar; 109(3):263-9. PubMed ID: 23339876
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early benefit assessment of new drugs in Germany - results from 2011 to 2012.
    Hörn H; Nink K; McGauran N; Wieseler B
    Health Policy; 2014 Jun; 116(2-3):147-53. PubMed ID: 24472328
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of additive or substitutive clinical study design on the negotiated reimbursement for oncology pharmaceuticals after early benefit assessment in Germany.
    Dintsios CM; Beinhauer I
    Health Econ Rev; 2020 Mar; 10(1):7. PubMed ID: 32172494
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ten years of German benefit assessment: price analysis for drugs with unproven additional benefit.
    Kleining K; Laufenberg J; Thrun P; Ehlert D; Wasem J; Bartol A
    Health Econ Policy Law; 2024 Apr; 19(2):216-233. PubMed ID: 37577932
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Arbitration Board Setting Reimbursement Amounts for Pharmaceutical Innovations in Germany When Price Negations between Payers and Manufacturers Fail: An Empirical Analysis of 5 Years' Experience.
    Ludwig S; Dintsios CM
    Value Health; 2016 Dec; 19(8):1016-1025. PubMed ID: 27987628
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Price benchmarks of drugs selected for Medicare price negotiation and their therapeutic alternatives.
    Hernandez I; Cousin EM; Wouters OJ; Gabriel N; Cameron T; Sullivan SD
    J Manag Care Spec Pharm; 2024 Aug; 30(8):762-772. PubMed ID: 38905356
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early benefit assessment of pharmaceuticals in Germany: manufacturers' expectations versus the Federal Joint Committee's decisions.
    Fischer KE; Stargardt T
    Med Decis Making; 2014 Nov; 34(8):1030-47. PubMed ID: 25149822
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmaceutical Pricing in Germany: How Is Value Determined within the Scope of AMNOG?
    Lauenroth VD; Stargardt T
    Value Health; 2017; 20(7):927-935. PubMed ID: 28712622
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estimated discounts generated by Medicare drug negotiation in 2026.
    Hernandez I; Gabriel N; Dickson S
    J Manag Care Spec Pharm; 2023 Aug; 29(8):868-872. PubMed ID: 37523318
    [No Abstract]   [Full Text] [Related]  

  • 14. Timeliness of Health Technology Assessments and Price Negotiations for Oncology Drugs in Canada.
    Rawson NSB; Stewart DJ
    Clinicoecon Outcomes Res; 2024; 16():437-445. PubMed ID: 38812711
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Information on new drugs at market entry: retrospective analysis of health technology assessment reports versus regulatory reports, journal publications, and registry reports.
    Köhler M; Haag S; Biester K; Brockhaus AC; McGauran N; Grouven U; Kölsch H; Seay U; Hörn H; Moritz G; Staeck K; Wieseler B
    BMJ; 2015 Feb; 350():h796. PubMed ID: 25722024
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 10 Years of AMNOG: What is the Willingness-to-Pay for Pharmaceuticals in Germany?
    Büssgen M; Stargardt T
    Appl Health Econ Health Policy; 2023 Sep; 21(5):751-759. PubMed ID: 37249741
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determinants of price negotiations for new drugs. The experience of the Italian Medicines Agency.
    Villa F; Tutone M; Altamura G; Antignani S; Cangini A; Fortino I; Melazzini M; Trotta F; Tafuri G; Jommi C
    Health Policy; 2019 Jun; 123(6):595-600. PubMed ID: 31097207
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Determinants of Orphan Drug Prices in Germany.
    Worm F; Dintsios CM
    Pharmacoeconomics; 2020 Apr; 38(4):397-411. PubMed ID: 31903523
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Estimated Changes in Manufacturer and Health Care Organization Revenue Following List Price Reductions for Hepatitis C Treatments.
    Dickson S; Reynolds I
    JAMA Netw Open; 2019 Jul; 2(7):e196541. PubMed ID: 31276176
    [TBL] [Abstract][Full Text] [Related]  

  • 20. "Market withdrawals" of medicines in Germany after AMNOG: a comparison of HTA ratings and clinical guideline recommendations.
    Staab TR; Walter M; Mariotti Nesurini S; Dintsios CM; Graf von der Schulenburg JM; Amelung VE; Ruof J
    Health Econ Rev; 2018 Sep; 8(1):23. PubMed ID: 30229501
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.